BEACON Pharmaceutical Ltd operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares BEACON Pharmaceutical Ltd with three other
pharmaceutical manufacturers in Asia:
Bora Pharmaceuticals Co Ltd
of TAIWAN
(2020
sales of 1.80 billion Taiwanese Dollars [US$64.80 million]
of which 73%
was Manufacture Department),
Jiangxi Synergy Pharmaceutical Co Ltd
of CHINA
(435.42 million Chinese Renmimbi [US$67.38 million]
of which 100%
was Pharmaceutical manufacture), and
Daebong LS Company Limited
which is
based in KOREA (SOUTH)
(76.25 billion Korean Won [US$64.51 million]
of which 80%
was Manufacturing).
Sales Analysis.
Sales were up sharply during the third
fiscal
quarter of 2021 versus the previous year's third quarter.
During the third
fiscal
quarter of 2021, sales at BEACON Pharmaceutical Ltd totalled
2.60 billion Bangladeshi Taka.
This is
an increase of 89.2%
from the 1.37 billion Bangladeshi Taka in sales at the company during the third quarter of 2020.
This was the biggest same quarter rise in sales at BEACON Pharmaceutical Ltd in the previous 26 quarters.
During the first three quarters of 2021, sales totalled 6.33 billion Bangladeshi Taka, which is
50.6% higher
than through the first three
fiscal
quarters of 2020.
During the previous 15 quarters, sales at BEACON Pharmaceutical Ltd have increased compared with the same quarter in the previous year.
BEACON Pharmaceutical Ltd reported sales of 5.59 billion Bangladeshi Taka (US$65.52 million)
for the
fiscal
year ending
June of 2020.
This
represents
an
increase of 20.3%
versus 2019, when the company's sales were 4.65 billion Bangladeshi Taka.
Sales at BEACON Pharmaceutical Ltd have increased during each of the previous five years
(and since 2015, sales have increased a total of 172%).